Company Overview and News


Add TEVA
to your dashboard

Headline News

How Did the New Indian Tax System Impact Abbott’s Established Pharmaceuticals Sales?

13m marketrealist
In 3Q17, the Indian government’s implementation of a new GST (goods and services tax) system came into effect on July 1, 2017, and impacted Abbott Laboratories’ (ABT) EPD (Established Pharmaceuticals Division) sales. The healthcare sector was generally impacted due to this development, and distribution partners decreased their inventory levels prior to the GST implementation, which led to fears of supply shortages. (193-0)

UPDATE 1-Teva Pharmaceutical set for major layoffs in Israel, U.S. -report

36m reuters
TEL AVIV, Nov 23 (Reuters) - Teva Pharmaceutical Industries is expected to cut 20-25 percent of its workforce in Israel, where it employs 6,860 people, and a few thousand more jobs are to go in the United States, financial news website Calcalist said on Thursday. (129-0)

Ovid Therapeutics: Is There More Upside After A 75% Gain In 3 Weeks?

58m seekingalpha
Shares have risen by 75% since bringing this stock to the attention of readers three weeks ago. (388-0)

Teva to Cut Up to 25% of Israel Workforce, Calcalist Says - Bloomberg

3h bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (129-0)

Teva Pharmaceutical set for major layoffs in Israel, US: report

4h channelnewsasia
Teva Pharmaceutical Industries is expected to cut 20-25 percent of its 6,860 workers in Israel and a few thousand more in the United States, financial news website Calcalist reported on Thursday. (129-0)

Teva Pharmaceutical set for major layoffs in Israel, U.S.: report

5h reuters
TEL AVIV (Reuters) - Teva Pharmaceutical Industries is expected to cut 20-25 percent of its 6,860 workers in Israel and a few thousand more in the United States, financial news website Calcalist reported on Thursday. (129-1)

Dr Reddys falls 2%, competition may rise for Vitorin that treats high cholesterol in blood

5h moneycontrol
Dr Reddy's Laboratories share price fell more than 2 percent intraday Thursday, owing to likely competition to Vitorin that treats high cholesterol in blood. (133-0)

How Did Teva’s CNS Portfolio Perform in 3Q17?

17h marketrealist
Teva Pharmaceutical Industries’ (TEVA) CNS (central nervous system) drugs generated 3Q17 revenues of $1.1 billion, which was ~12% lower YoY (year-over-year) and ~1% lower QoQ (quarter-over-quarter). From January 2017 to September 2017, or YTD (year-to-date) as of September 2017, CNS drugs generated revenues of ~$3.4 billion, which was ~15% lower YoY. (129-0)

How Teva’s Generic Medicines Business Is Positioned after 3Q17

18h marketrealist
Teva Pharmaceutical Industries’ (TEVA) Generic Medicine segment generated 3Q17 revenues of $3.0 billion, which was ~8% higher YoY (year-over-year) but ~2% lower QoQ (quarter-over-quarter). In US and European markets, the segment reported 3Q17 revenues of ~$1.2 billion and $985 million, respectively, compared with $1.3 billion and $933 million in 3Q16, representing a 9% fall and a 6% YoY rise, respectively. (129-0)

Inside Teva’s 3Q17 Performance

20h marketrealist
Teva Pharmaceutical Industries (TEVA) reported 3Q17 revenues of $5.6 billion, which represents a ~1% YoY (year-over-year) rise but a 1% QoQ (quarter-over-quarter) fall. Teva reported GAAP (generally accepted accounting principles) and non-GAAP operating income of $378 million and $1.47 billion, respectively, compared with $765 million and $1.79 billion, respectively, in 3Q16. (129-0)

Tracking David Abrams' Abrams Capital Management Portfolio - Q3 2017 Update

2017-11-22 seekingalpha
David Abrams’ 13F portfolio increased this quarter from $2.52B to $2.56B. The number of positions decreased from 19 to 18. (701-1)

Teva Pharmaceutical: Generidiculous!

2017-11-21 seekingalpha
Sure, Teva's growth trajectory has stalled with exclusivity loss of Copaxone and a $6.1 billion impairment charge but 4.6x 2018 EPS estimates? Really? (206-0)

Millions of Patients Face Pain and Withdrawal as Opioid Prescriptions Plummet - Bloomberg

2017-11-21 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (129-0)

15 Current Wall Street Favorites - Cramer's Mad Money (11/20/17)

2017-11-21 seekingalpha
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday, November 20. (286-0)

Doctors Are Cutting Off Opioids, Leaving Millions of Patients Facing Pain and Withdrawal - Bloomberg

2017-11-21 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (129-0)

Stock Research Report

Teva Pharmaceutical Industries is global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic medicines and a focused portfolio of specialty medicines. The company operate worldwide, with a significant presence in the United States, Europe and many other markets around the world. Its key strengths include itsworld-leading generics expertise and portfolio, focused specialty portfolio, robust R&D capabilities, global infrastructure and scale and dedicated leadership and employees.

Teva Pharmaceutical believe company is strategically positioned to benefit from market, economic and regulatory trends in global healthcare. These trends include aging populations, the increasing prevalence of chronic diseases, economic pressure on governments and private payors to provide affordable healthcare solutions, legislative and regulatory reforms, scientific and technological advances, increased patient awareness...

Click for full article
CUSIP: 881624209